HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases
HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases
复制标题
DOI：
10.1007/s13277-011-0204-3
复制
发表时间：
2011-12-01
期刊：
影响因子：
--
通讯作者：
Pahisa, Jaume
中科院分区：
文献类型：
--
作者：
Molina, Rafael;Escudero, Jose M.;Pahisa, Jaume
本研究的目的是评估一种新的肿瘤标志物，HE 4，在健康女性和良性和恶性妇科疾病患者中与CA 125和卵巢癌风险算法（ROMA）进行比较。本文对66例健康妇女、285例妇科良性疾病（子宫内膜异位症68例、子宫肌瘤56例、卵巢囊肿137例、其它疾病24例）、33例非活动性妇科恶性肿瘤和143例活动性妇科恶性肿瘤（卵巢癌111例）进行了血清CA 125和HE 4测定。CA 125和HE 4的临界值分别为35 U/mL和150 pmol/L。绝经前或绝经后女性的ROMA算法临界值分别为13.1和27.7。HE 4、CA 125和ROMA异常率分别为1.5%、13.6%和25.8%，良性疾病患者分别为1.1%、30.2%和12.3%。在癌症患者中，HE 4（与CA 125相反）在卵巢癌中的浓度显著高于其他恶性肿瘤（p
The aim of this study is to evaluate a new tumour marker, HE4, in comparison with CA 125 and the Risk of Ovarian Malignancy Algorithm (ROMA) in healthy women and in patients with benign and malignant gynaecological diseases. CA 125 and HE4 serum levels were determined in 66 healthy women, 285 patients with benign gynaecological diseases (68 endometriosis, 56 myomas, 137 ovarian cysts and 24 with other diseases), 33 patients with non-active gynaecological cancer and 143 with active gynaecological cancer (111 ovarian cancers). CA 125 and HE4 cut-offs were 35 U/mL and 150 pmol/L, respectively. ROMA algorithm cut-off was 13.1 and 27.7 for premenopausal or postmenopausal women, respectively. HE4, CA 125 and ROMA results were abnormal in 1.5%, 13.6% and 25.8% of healthy women and in 1.1%, 30.2% and 12.3% of patients with benign diseases, respectively. Among patients with cancer, HE4 (in contrast to CA 125) had significantly higher concentrations in ovarian cancer than in other malignancies (p